Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million

Reuters03-30

Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million

Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.
Revenue rose 8.1% to RMB 780 million.
Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.
Selling and distribution expenses climbed to RMB 340.9 million, while R&D costs edged down to RMB 147.6 million.
Business updates highlighted two new China launches, Boyouping (dulaglutide) in August and Boyoujing (aflibercept) in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12080547), on March 30, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623341913?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623341913","market":"fut","top_or_hot":-1,"title":"Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.\n        </li>\n<li>\n          Revenue rose 8.1% to RMB 780 million.\n        </li>\n<li>\n          Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.\n        </li>\n<li>\n          Selling and distribution expenses climbed to RMB 340.9 million, while R&amp;D costs edged down to RMB 147.6 million.\n        </li>\n<li>\n          Business updates highlighted two new China launches, Boyouping (dulaglutide) in August and Boyoujing (aflibercept) in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12080547), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-30 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.\n        </li>\n<li>\n          Revenue rose 8.1% to RMB 780 million.\n        </li>\n<li>\n          Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.\n        </li>\n<li>\n          Selling and distribution expenses climbed to RMB 340.9 million, while R&amp;D costs edged down to RMB 147.6 million.\n        </li>\n<li>\n          Business updates highlighted two new China launches, Boyouping (dulaglutide) in August and Boyoujing (aflibercept) in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12080547), on March 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"601607","symbol_name":"上海医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL5HctGt:1","article_id":"2623341913","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623341913","pubTimestamp":1774882833,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.Selling and distribution expenses climbed to RMB 340.9 million, while R&D costs edged down to RMB 147.6 million.Business updates highlighted two new China launches, Boyouping  in August and Boyoujing  in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 30, 2026, and is solely respons","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念","BK0187":"一线龙头","BK0028":"国家队","BK1191":"制药","BK1161":"生物科技","BK0175":"白马股","BK0099":"上海本地重组","BK0209":"零售","BK1606":"中医药概念","BK0196":"行业龙头","BK0097":"医药电商","BK1583":"高瓴概念","BK0020":"浦东新区","02186":"绿叶制药","06955":"博安生物","BK0184":"上海国资改革"},"translate_title":"博安生物25财年利润下降90.24%至710万元人民币；收入增长8.1%至人民币7.8亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":0.9,"02186":0.9,"06955":0.9},"content_text":"Boan Biotech FY25 profit drops 90.24% to RMB 7.1 million; revenue rises 8.1% to RMB 780 million\n    \n\n\n          Boan Biotech reported FY2025 net profit of RMB 7.1 million, down 90.2%.\n        \n\n          Revenue rose 8.1% to RMB 780 million.\n        \n\n          Profit before tax dropped to RMB 7.1 million from RMB 73.2 million.\n        \n\n          Selling and distribution expenses climbed to RMB 340.9 million, while R&D costs edged down to RMB 147.6 million.\n        \n\n          Business updates highlighted two new China launches, Boyouping (dulaglutide) in August and Boyoujing (aflibercept) in November, alongside multiple licensing deals including mainland commercialization of Boyouping granted to Shanghai Pharmaceutical.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260330-12080547), on March 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623341913","isCrawlerRequest":true}